Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · mng-umap@100

MNG1166

—

0afdaf51-38b6-5cc0-9813-61157fe13d94

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
—

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • ANGIOGENESIS+0.512
  • EPITHELIAL_MESENCHYMAL_TRANSITION+0.495
  • IL6_JAK_STAT3_SIGNALING+0.491
  • INTERFERON_GAMMA_RESPONSE+0.472
  • COAGULATION+0.441
  • ALLOGRAFT_REJECTION+0.427
  • COMPLEMENT+0.391
  • INTERFERON_ALPHA_RESPONSE+0.390
  • INFLAMMATORY_RESPONSE+0.379
  • APICAL_SURFACE+0.375

Top 10 suppressed

  • PROTEIN_SECRETION-0.530
  • UNFOLDED_PROTEIN_RESPONSE-0.407
  • OXIDATIVE_PHOSPHORYLATION-0.391
  • MYC_TARGETS_V1-0.385
  • MYC_TARGETS_V2-0.377
  • DNA_REPAIR-0.357
  • TGF_BETA_SIGNALING-0.322
  • MTORC1_SIGNALING-0.313
  • CHOLESTEROL_HOMEOSTASIS-0.277
  • ANDROGEN_RESPONSE-0.274

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

5 twins match this tumor's tissue · 5 come from a different tissue of origin ← cross-tissue dominant

#SampleCancer typeSubtypecos similarity
1MNG276
mng-umap@100
——0.940
2R426
bladder-landscape@3
——0.926
3R101
bladder-landscape@3
——0.920
4SJEPD029_D.RNA-Seq
medullo-epn-umap@date-based
EPNPosterior Fossa EPN0.915
5BS_JT82QGXF
medullo-epn-umap@date-based
MedMedulloblastoma0.912
6SRR1389059
brain-umap@2
GTEX—0.909
7SJEPD001535_R2.RNA-Seq
medullo-epn-umap@date-based
EPNPosterior Fossa EPN0.905
8MNG303
mng-umap@100
——0.902
9MNG133
mng-umap@100
——0.901
10MDT-AP-2621
medullo-epn-umap@date-based
MedMedulloblastoma0.900

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 27 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
ANGIOGENESIS0.512Remibrutinib— uncovered
EPITHELIAL_MESENCHYMAL_TRANSITION0.495Inavolisib— uncovered
IL6_JAK_STAT3_SIGNALING0.491Inavolisib— uncovered
INTERFERON_GAMMA_RESPONSE0.472Idelalisib— uncovered
COAGULATION0.441Binimetinib— uncovered
ALLOGRAFT_REJECTION0.427Idelalisib— uncovered
COMPLEMENT0.391Inavolisib— uncovered
INTERFERON_ALPHA_RESPONSE0.390Inavolisib— uncovered
INFLAMMATORY_RESPONSE0.379Idelalisib— uncovered
APICAL_SURFACE0.375Temsirolimus— uncovered
PANCREAS_BETA_CELLS0.361Cobimetinib— uncovered
KRAS_SIGNALING_UP0.344Inavolisib— uncovered
MYOGENESIS0.304Inavolisib— uncovered
TNFA_SIGNALING_VIA_NFKB0.289Inavolisib— uncovered
APICAL_JUNCTION0.241Inavolisib— uncovered
IL2_STAT5_SIGNALING0.231Idelalisib— uncovered
KRAS_SIGNALING_DN0.213Remibrutinib— uncovered
SPERMATOGENESIS0.212Inavolisib— uncovered
HYPOXIA0.152Idelalisib— uncovered
ESTROGEN_RESPONSE_LATE0.099Idelalisib— uncovered